Bank of America Spends $250M Annually on GLP-1 Weight Loss Drugs

Bank of America CEO Brian Moynihan revealed on Wednesday that the company spends over $250 million per year on GLP-1 weight loss drugs for its approximately 211,000 employees. Moynihan described the expenditure as a sound investment in the workforce, according to CNBC. The announcement highlights the growing corporate adoption of costly weight-loss medications as part of employee health benefits. The bank's spending on these drugs underscores the significant financial commitment companies are making to address obesity and related health issues among their staff. The revelation came during a public statement, though specific details on the program's structure or employee participation were not disclosed. This move reflects a broader trend of large employers covering GLP-1 drugs, which have surged in popularity and cost. The annual figure positions Bank of America among the major corporate spenders on such treatments, raising questions about the sustainability and long-term implications for healthcare budgets.